Cigarette smoking at diagnosis or during therapy correlates with poor outcome in patients with lung and esophageal cancers, yet the underlying mechanisms remain unknown. In this study, we found that exposure of esophageal cancer cells to cigarette smoke condensate led to upregulation of the xenobiotic pump ABCG2, which is expressed in cancer stem cells and confers treatment resistance in lung and esophageal carcinomas, and increased the side population of lung cancer cells containing cancer stem cells. Upregulation of ABCG2 coincided with increased occupancy of aryl hydrocarbon receptor (AhR), Sp1, and Nrf2 within its promoter, and deletion of xenobiotic response elements and/or Sp1 sites markedly attenuated ABCG2 induction. Under conditions potentially achievable in clinical settings, treatment with mithramycin diminished basal as well as cigarette smoke condensate-mediated increases in AhR, Sp1, and Nrf2 levels within the ABCG2 promoter, markedly down-regulated ABCG2, and inhibited proliferation and tumorigenicity of lung and esophageal cancer cells. Micro-array analyses revealed that mithramycin targeted multiple stem cell-related pathways in vitro and in vivo. Collectively, our findings provide a potential mechanistic link between smoking status and outcome of patients with lung and esophageal cancers and support clinical use of mithramycin for repressing ABCG2 and inhibiting stem cell signaling in thoracic malignancies.
Mithramycin Represses Basal and Cigarette Smoke-Induced Expression of ABCG2 and Inhibits Stem Cell Signaling in Lung and Esophageal Cancer Cells
Mary Zhang Thoracic Oncology Section; 2 Gastrointestinal and Hepatobiliary Malignancies Section; Surgery Branch; 3 Laboratory of Pathology; 5 Clinical Pharmacy Department; 6 Experimental Therapeutics Section, Medical Oncology Branch; Center for Cancer Research, National Cancer Institute, Bethesda, Maryland.
Introduction
Lung and esophageal cancers are leading causes of cancer-related deaths worldwide (1) .
In 2011, these malignancies accounted for an estimated 1.8 million deaths globally; in the United States, nearly 160,000 deaths were attributed to lung cancer, whereas 15,000 deaths were due to esophageal carcinoma (2) . Presently, 80% of lung cancers, and 50% of esophageal carcinomas are directly attributable to cigarette smoke (3, 4) . Currently, more than 1.3 billion people smoke; hence, the global burden of tobacco-associated thoracic malignancies will continue to increase, with particularly devastating consequences in developing countries (5) .
In addition to being a significant risk factor for major morbidity and mortality in individuals undergoing potentially curative resections (6, 7) , cigarette smoking diminishes responses to chemo-and radiation therapy, enhances systemic metastases, and decreases survival of patients with locally advanced or disseminated lung and esophageal cancers (8) (9) (10) (11) ; the mechanisms underlying these phenomena have not been fully established. Previously, we reported that under clinically relevant exposure conditions, cigarette smoke enhances tumorigenicity of lung cancer cells via polycomb-mediated repression of Dickkopf-1 (Dkk1), which encodes an antagonist of Wnt signaling (12) . In unpublished studies, we observed a similar phenomenon in esophageal adenocarcinoma cells following cigarette smoke exposure.
Additionally, we have observed that cigarette smoke activates miR-31, targeting Dkk1 as well as several other Wnt antagonists in lung cancer cells; constitutive expression of this microRNA significantly enhances proliferation of lung cancer cells in-vitro and in-vivo (13) . In more recent studies, we observed that cigarette smoke mediates epigenetic repression of miR-487b in lung cancer cells, resulting in over-expression of polycomb group proteins BMI1 and SUZ12, as well as Wnt5A, k-ras and C-myc, all of which have been implicated in modulating stem cell pluripotency (14) (15) (16) (17) (18) ; consistent with these observations, knock-down of miR-487b increases proliferation and tumorigenicity of lung cancer cells (Xi et al, submitted) . The present study was undertaken to examine if cigarette smoke activates additional stem cell-associated genes, which enhance the malignant phenotype of lung and esophageal cancers in an effort to develop novel pharmacologic strategies for treatment of these neoplasms.
Materials and Methods
Cell Lines and Treatment Conditions: Unless otherwise specified, all cancer lines were obtained from American Type Culture Collection (ATCC Manassas, VA). Cells were validated by periodic HLA typing of lab cultures relative to new cell aliquots from the repository. NCI-SBEsC1 and NCI-SB-EsC2 (EsC1 and EsC2, respectively) were established in our lab from two patients with esophageal adenocarcinoma who developed disease recurrence after undergoing induction chemo/XRT and surgery on IRB approval protocols; these cell lines exhibit HLA as well as cytokeratin expression profiles identical to the respective primary tumors. All cancer lines were maintained in Roswell Park Memorial Institute (RPMI) media supplemented with 10% Fetal Bovine Serum (FBS), and 1% penicillin/streptomycin (normal media; NM). Primary normal human small airway epithelial cells (SAEC) were obtained from Lonza, Inc. (Fredrick, MD), and cultured per vendor instructions. Cigarette smoke condensates (CSC) were generated as described (19) . For smoke exposure experiments, cells were cultured in appropriate normal media with or without varying concentrations of CSC. Media and CSC were changed daily.
Cells were subcultured as necessary, and harvested at appropriate times for further analysis.
Mithramycin was obtained from either Sigma (St. Louis, MO) or the Developmental Therapeutics Program (NCI). For drug exposure treatments, cells were cultured in NM with or without CSC. Media was changed and mithramycin was added at various concentrations for 24 hours; cells were harvested at indicated time points for further analysis.
RNA Isolation, Real-time Quantitative Reverse Transcription-PCR, and Microarray Analysis:
Total RNA was isolated and real-time quantitative reverse transcription-PCR (qRT-PCR) was performed as described (19) Figure 1D ). Additionally, knock-down of ABCG2 significantly inhibited soft agar clonogenicity of A549 cells ( Figure 1D ). This phenomenon could not be assessed in EsC2 cells, which exhibit poor clonogenicity in soft agar. In additional experiments, shRNA techniques were used to knock-down HDAC6, which is required for activation and nuclear transport of AhR in response to tobacco carcinogens (26) .
Results
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qRT-PCR and immunofluorescence experiments confirmed decreased HDAC6 expression in knock-down cells relative to respective controls transduced with sham sequences ( Figure 2D; upper panel). Knock-down of HDAC 6 only modestly diminished CSC-mediated induction of ABCG2 in A549, EsC1, and EsC2 cells ( Figure 2D ; lower panel); the effects of HDAC6 inhibition could not be assessed in Calu-6 cells due to toxicity of the shRNA construct in these cells. Collectively, these findings suggested that induction of ABCG2 by CSC was not mediated solely by AhR signaling.
In addition to xenobiotic response elements (XRE) that are binding sites for AhR, the ABCG2 promoter contains a number of Specificity protein 1 (Sp1) sites (24) Results pertaining to Calu-6 cells (simultaneously processed for qRT-PCR experiments in Figure   3B ) are depicted in Figure 3D . CSC-mediated activation of ABCG2 coincided with increased levels of RNA polymerase II (pol II) and H3K9Ac, with decreased levels of H3K9Me3 (activation and repression marks, respectively) within the ABCG2 promoter. CSC induced recruitment of Sp1, AhR, and Nrf2 to the ABCG2 promoter; these results were most dramatic for Sp1, and were consistent with aforementioned luciferase experiments. Mithramycin diminished CSC-mediated occupancy of these transcription factors within the ABCG2 promoter; these effects coincided with appropriate alterations in pol II, H3K9Ac and H3K9Me3. genes were modulated by mithramycin under both doses, 100 of which are listed in Table 2 .
Effects of Mithramycin on Proliferation and Tumorigenicity of Cancer
ABCG2 was down-regulated > 2 fold in xenografts from mice receiving 2mg/kg but not 1mg/kg mithramycin. All eight of the stem-cell related pathways modulated in-vitro by mithramycin, were also targeted in tumor xenografts by systemic drug treatment, albeit to a somewhat lesser degree (Table 1B) . A similar phenomenon was observed regarding the remaining 8 canonical pathways listed in Table 1A . A variety of networks regulating intracelleular signaling, DNA damage response, chromatin remodeling, and chromosomal replication were inhibited in A549 tumor xenografts following mithramycin treatment (Supplementary Figure 3) . 
Discussion
The vast majority of lung and esophageal carcinomas are directly attributable to tobacco abuse (3, 4) . Cigarette smoking not only facilitates initiation and preclinical progression of lung and esophageal cancers, but also enhances treatment resistance and dissemination of established malignancies, thereby decreasing overall survival of patients with these neoplasms (8, 10, 11, 31) . Delineation of the mechanisms by which cigarette smoke promotes proliferation of lung and esophageal carcinomas may facilitate development of more efficacious treatment regimens for these malignancies.
Our previous studies have shown that cigarette smoke increases the malignant phenotype of lung and esophageal cancer cells, in part, by up-regulating genes, which mediate stem cell phenotype (12, 13) . Consistent with these observations, our current experiments revealed that cigarette smoke mediates time-and dose-dependent up-regulation of ABCG2 in lung and esophageal cancer cells; this phenomenon appeared to be considerably less pronounced in cultured normal aerodigestive tract epithelia. As expected, CSC-mediated up-regulation of ABCG2 in cancer cells coincided with increased SP fraction; these findings suggest, although certainly do not prove that cigarette smoke promotes expansion of pluripotent tumor cells (21) .
Further analysis revealed that CSC-mediated activation of ABCG2 coincided with recruitment of AhR and Nrf2, as well as Sp1 to the ABCG2 promoter. Mithramycin repressed basal as well as CSC-mediated induction of ABCG2; these effects may be attributable to direct inhibition of binding of Sp1 to DNA (27) , and decreased expression of Sp1, as well as AhR and Nrf2 (two potential targets of Sp1) (28) , which are known to activate ABCG2. Additionally, mithramycin dramatically decreased proliferation and tumorigenicity of cancer cells. Growth inhibition coincided with down-regulation of ABCG2, as well as numerous other genes mediating "stemness", proliferation, and metastatic potential of cancer cells. To the best of our knowledge, these experiments represent the most comprehensive analysis of mechanisms regulating ABCG2 expression in thoracic malignancies following exposure to cigarette smoke, and are the first to demonstrate the potential of mithramycin for targeting ABCG2 as well as other stem cell-related genes in thoracic malignancies. ABCG2 (BCRP) is a member of the ATP binding cassette (ABC) transporters, which functions as a xenobiotic pump in many normal tissues (32) . Its substrates include numerous environmental toxins as well as chemotherapeutic agents. Our experiments demonstrated that knock-down of ABCG2 inhibits proliferation, migration, and clonogenicity of lung and esophageal cancer cells; these findings suggest that ABCG2 modulates intracellular processes other than extrusion of xenobiotics. Several recent studies suggest that ABCG2 is a critical mediator of stem cell homeostasis. For example, ABCG2 is an essential upstream mediator of sonic-hedgehog signaling, which has been implicated in maintenance of stemness (33) .
Furthermore, ABCG2 binds to heme, thereby diminishing intracellular porphyrin levels, rendering stem cells resistant to hypoxia (34) . Constitutive expression of ABCG2 protects cardiac stem cells from oxidative stress (35) , and enhances expansion, while impairing maturation of hematopoietic progenitor cells (36) . Of particular relevance regarding our current study are recent reports demonstrating that increased expression of ABCG2 correlates with chemo-resistance and stem-like phenotype of lung and esophageal carcinomas (21, 23, (37) (38) (39) , and decreased survival of patients with these neoplasms (40) (41) (42) .
Despite the fact that knock-down of ABCG2 decreased proliferation, migration and clonogenicity of lung and esophageal cancer cells, our current data do not establish, nor imply that down-regulation of ABCG2 is the primary mechanism by which mithramycin inhibits proliferation and tumorigenicity of these cancer cells. Indeed, our micro-array analysis revealed that mithramycin significantly down-regulated hundreds of genes mediating stem cell signaling, cell cycle progression, chromatin remodeling, and DNA damage response. Although experiments are underway to examine this issue, it seems unlikely that constitutive overexpression of ABCG2 would significantly diminish mithramycin-mediated cytotoxicity in cultured cancer cells, unless this agent is a substrate for ABCG2. In all likelihood, the antitumor effects of mithramycin are mediated by direct inhibition of Sp1 binding to promoters of master genes regulating diverse cellular functions, with subsequent repression of down-stream targets by direct as well as indirect mechanisms (30, 43) .
Mithramycin, a polyauroleic acid isolated from streptomyces, was initially evaluated as a chemotherapeutic agent in cancer patients during the 1960's and 70's (44), but was discontinued due to excessive systemic toxicities (45) . Recently there has been renewed interest in clinical development of mithramycin and its derivatives because of their ability to specifically inhibit binding of Sp1 to GC-rich DNA (27) , and down-regulate numerous genes mediating proliferation, invasion and metastasis of cancer cells (46) (47) (48) . Of particular interest in this regard are recent studies indicating that currently approved agents such as cyclo-oxygenase inhibitors markedly enhance mithramycin mediated-inhibition of Sp1 expression/ activity in cancer cells (49) . Such combinational strategies could enable reduction of mithramycin doses, and possibly decrease systemic toxicities in clinical settings.
Our current findings have direct translational implications regarding evaluation of mithramycin in patients with thoracic malignancies. Extrapolation of data from previous animal studies (50) suggests that mithramycin levels achieved in our xenograft experiments were in the 50-200 nM range over 24h; these exposure conditions, which closely approximated those used for our in-vitro experiments, are potentially achievable using previous mithramycin dosing schedules in humans (44) . Collectively our findings support the clinical evaluation of mithramycin as a strategy to repress ABCG2 and inhibit signaling pathways mediating "stemness" in thoracic malignancies. 
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